What is claimed is:

1. An isolated human monospecific antibody that binds human CD3 with a binding dissociation equilibrium constant (K_D) of less than about 1 nM as measured in a surface plasmon resonance assay at 25ºC, wherein the antibody comprises three complementarity determining regions (CDRs) within a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 242, 258, 274, 290, 306, 322, 338, 354, 386, 402, 418, 434, 466, 482, 514, 530, 594, 610, 626, 642, 706, 722, 738, 754, 770, 786, 802, 850, 866, 882, 898, 930, 946, 962, 1026, 1042, 1050, 1058, 1066, 1074, 1082, 1098, 1106, 1114, 1122, 1138, 1146, 1154, 1162, 1170, 1178, and 1186, and three CDRs within a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 250, 266, 282, 298, 314, 330, 346, 362, 394, 410, 426, 442, 474, 490, 522, 538, 602, 618, 634, 650, 714, 730, 746, 762, 778, 794, 810, 858, 874, 890, 906, 938, 954, 970, 1034, and 1234.

2. The isolated human monospecific antibody of claim 1, wherein the antibody binds human CD3 with a K_D of less than 500 pM as measured in a surface plasmon resonance assay at 25ºC.

3. The isolated human monospecific antibody of claim 2, wherein the antibody binds human CD3 with a K_D of less than 100 pM as measured in a surface plasmon resonance assay at 25ºC.

4. The isolated human monospecific antibody of claim 1 that binds human CD3 with a dissociative half-life (t½) of greater than 10 minutes as measured in a surface plasmon resonance assay at 25ºC.

5. The isolated human monospecific antibody of claim 4, wherein the antibody binds human CD3 with a t½ of greater than 100 minutes as measured in a surface plasmon resonance assay at 25ºC.

6. The isolated human monospecific antibody of claim 1, wherein the antibody comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 386/394, 402/410, 418/426, 434/442, 466/474, 482/490, 514/522, 530/538, 594/602, 610/618, 626/634, 642/650, 706/714, 722/730, 738/746, 754/762, 770/778, 786/794, 802/810, 850/858, 866/874, 882/890, 898/906, 930/938, 946/954, 962/970, 1026/1034, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

7. The isolated human monospecific antibody of claim 6, wherein the comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; and 1050/1234.

8. The isolated antibody of claim 7, wherein the antibody comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, selected from the group consisting of: SEQ ID NOs: 4-6-8-12-14-16; 116-118-120-124-126-128; 516-518-520-524-526-528; 772-774-776-780-782-784; 1052-1054-1056-1236-1238-1240; and 1092-1094-1096-1236-1238-1240.

9. The isolated human monospecific antibody of claim 1, wherein the antibody comprises: a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 242, 258, 274, 290, 306, 322, 338, 354, 386, 402, 418, 434, 466, 482, 514, 530, 594, 610, 626, 642, 706, 722, 738, 754, 770, 786, 802, 850, 866, 882, 898, 930, 946, 962, 1026, 1042, 1050, 1058, 1066, 1074, 1082, 1098, 1106, 1114, 1122, 1138, 1146, 1154, 1162, 1170, 1178, and 1186; and a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 250, 266, 282, 298, 314, 330, 346, 362, 394, 410, 426, 442, 474, 490, 522, 538, 602, 618, 634, 650, 714, 730, 746, 762, 778, 794, 810, 858, 874, 890, 906, 938, 954, 970, 1034, and 1234.

10. The isolated human monospecific antibody of claim 9 that binds human CD3, wherein the antibody comprises: (a) a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2; 114; 514; 770; and 1050; and (b) a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10; 122; 522; 778; 1234; and 1234.

11. The isolated human monospecific antibody of claim 9, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 386/394, 402/410, 418/426, 434/442, 466/474, 482/490, 514/522, 530/538, 594/602, 610/618, 626/634, 642/650, 706/714, 722/730, 738/746, 754/762, 770/778, 786/794, 802/810, 850/858, 866/874, 882/890, 898/906, 930/938, 946/954, 962/970, 1026/1034, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

12. The isolated human monospecific antibody of claim 10, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; and 1050/1234.

13. The isolated human monospecific antibody of claim 9, wherein the antibody induces human T-cell proliferation and monkey T-cell proliferation in vitro, and wherein the antibody comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 114/122, 706/714, 722/730, 738/746, 770/778, 786/794, 802/810, 866/874, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

14. The isolated human monospecific antibody of claim 13, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 114/122, 706/714, 722/730, 738/746, 770/778, 786/794, 802/810, 866/874, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

15. A pharmaceutical composition comprising the antibody of any one of claims 1 to 14, and a pharmaceutically acceptable carrier or diluent.

16. Use of a pharmaceutical composition of claim 15 in the manufacture of a medicament for treating a tumor in a subject in need thereof.

What is claimed is:

1. An isolated human monospecific antibody that binds human CD3 with a binding dissociation equilibrium constant (K_D) of less than 5 nM as measured in a surface plasmon resonance assay at 25ºC, wherein the antibody comprises six complementarity determining regions (CDRs) within a heavy chain variable region (HCVR)/light chain variable region (LCVR) amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 386/394, 402/410, 418/426, 434/442, 466/474, 482/490, 514/522, 530/538, 594/602, 610/618, 626/634, 642/650, 706/714, 722/730, 754/762, 770/778, 786/794, 802/810, 850/858, 866/874, 882/890, 898/906, 930/938, 946/954, 962/970, and 1026/1034.

2. The isolated human monospecific antibody of claim 1, wherein the antibody binds human CD3 with a K_D of less than 500 pM as measured in a surface plasmon resonance assay at 25ºC.

3. The isolated human monospecific antibody of claim 2, wherein the antibody binds human CD3 with a K_D of less than 100 pM as measured in a surface plasmon resonance assay at 25ºC.

4. The isolated human monospecific antibody of claim 1 that binds human CD3 with a dissociative half-life (t½) of greater than 10 minutes as measured in a surface plasmon resonance assay at 25ºC.

5. The isolated human monospecific antibody of claim 4, wherein the antibody binds human CD3 with a t½ of greater than 100 minutes as measured in a surface plasmon resonance assay at 25ºC.

6. The isolated human monospecific antibody of claim 1, wherein the antibody comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 114/122; 514/522; and 770/778.

7. The isolated human monospecific antibody of claim 6, wherein the antibody comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, selected from the group consisting of: SEQ ID NOs: 4-6-8-12-14-16; 116-118-120-124-126-128; 516-518-520-524-526-528; and 772-774-776-780-782-784.

8. The isolated human monospecific antibody of claim 1, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 386/394, 402/410, 418/426, 434/442, 466/474, 482/490, 514/522, 530/538, 594/602, 610/618, 626/634, 642/650, 706/714, 722/730, 754/762, 770/778, 786/794, 802/810, 850/858, 866/874, 882/890, 898/906, 930/938, 946/954, 962/970, and 1026/1034.

9. The isolated human monospecific antibody of claim 6, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 114/122; 514/522; and 770/778.

10. The isolated human monospecific antibody of claim 8, wherein the antibody induces human T-cell proliferation and monkey T-cell proliferation *in vitro*, and wherein the antibody comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 114/122, 706/714, 722/730, 770/778, 786/794, 802/810, and 866/874.

11. The isolated human monospecific antibody of claim 10, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 114/122, 706/714, 722/730, 770/778, 786/794, 802/810, and 866/874.

12. A pharmaceutical composition comprising the antibody of any one of claims 1 to 11, and a pharmaceutically acceptable carrier or diluent.

13. Use of a pharmaceutical composition of claim 12 in the manufacture of a medicament for treating a tumor in a subject in need thereof.